Loading
HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Recognised by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.
CIViC holds 24 clinical evidence items and 2 assertions across 12 variants, naming Vemurafenib, Selumetinib, Cetuximab and Erlotinib and others. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes genetic literature 0.79, clinical 0.16, affected pathway 0.90, literature 0.98, genetic association 0.86, somatic mutation 0.97, animal model 0.43). IntOGen calls it a driver in 23 cohorts (23 activating, 0 loss-of-function), covering Angiosarcoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma and others. In OnCo, 1 product record names it (JYP0015).
In plain words · HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.
No product in this corpus aims at HRAS yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: 1 of 1 medicines aimed at it name a mutant, fusion, exon or hotspot in their mechanism (JYP0015), an alteration absent from normal cells. HPA HRAS: RNA tissue enhanced (brain 124 nTPM); high antibody staining in 7 normal tissues; highest cancer staining ovarian cancer (2 of 9 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Thyroid cancer, Sarcomas (soft tissue, bone, GIST), Head and neck squamous cell carcinoma, Neuroendocrine tumours, Prostate cancer, Colorectal cancer and more); Open Targets associates it with 9 specific cancer types at or above 0.5 (linear nevus sebaceous syndrome, urinary bladder cancer, nevus, epidermal, urinary bladder carcinoma, thyroid cancer, nonmedullary, 2, large congenital melanocytic nevus and more). (Rule 4 of scripts/fetch-target-specificity.ts.)
Sources: ClinicalTrials.gov: trials of JYP0015; Human Protein Atlas HRAS tissue; Open Targets ENSG00000174775 associations
First described 1982. Earliest sequence paper UniProt cites for the protein: Tabin C.J. et al, Nature, 1982, "Mechanism of activation of a human oncogene". Source.
Sources: HGNC HGNC:5173 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01112 (protein name, function text, keywords and locations (REST API)); CIViC gene HRAS (24 evidence items, 2 assertions, 12 variants; diseases: Skin Squamous Cell Carcinoma, Cancer, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma, Head And Neck Cancer and 4 more (GraphQL API, CC0)); Open Targets ENSG00000174775 (association with cancer (MONDO_0004992) 0.90; per-cancer scores at or above 0.5: urinary bladder cancer 0.79, head and neck squamous cell carcinoma 0.66, sarcoma 0.67, thyroid cancer 0.77, neuroendocrine neoplasm 0.64, skin cancer 0.54 (GraphQL API, CC0)); IntOGen HRAS (driver in 23 cohorts (Act 23, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Signal transducer in the Ras-MAPK signalling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Recognised by LZTR1 that mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. Location: Cell membrane; Golgi apparatus; Golgi apparatus membrane; Nucleus (UniProt). Locus 11p15.5 (HGNC).
RNA: tissue enhanced (brain 124 nTPM), detected in all normal tissues.
Medium: Bone marrow, Cerebellum, Cerebral cortex, Endometrium, Epididymis, Fallopian tube, Kidney, Lymph node.
Medium only: carcinoid, endometrial cancer, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HRAS" OR ABSTRACT:"HRAS" OR TITLE:"HRas proto-oncogene, GTPase" OR ABSTRACT:"HRas proto-oncogene, GTPase" OR TITLE:"GTPase HRas" OR ABSTRACT:"GTPase HRas" OR TITLE:"HRAS1" OR ABSTRACT:"HRAS1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HRAS, not a curated reading list.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, IntOGen.
Shares Thyroid cancer, Sarcomas (soft tissue, bone, GIST), Bladder & urothelial cancer, CIViC.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Thyroid cancer, CIViC, IntOGen, Breast cancer (all types).
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Breast cancer (all types).
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Head and neck squamous cell carcinoma.
Shares Thyroid cancer, Bladder & urothelial cancer, IntOGen, Breast cancer (all types).